Dr Thomas Bachelot
- Spécialité
- Oncologue médical, expert sein et gynécologie
- Titre
- Coordinateur adjoint de département
- Hôpital
- Centre Léon Bérard (Lyon)
- Derniers articles
-
- CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. (1 mars 2025)
- Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer. (1 janv. 2025)
- Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation. (1 déc. 2024)
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. (1 déc. 2024)
- Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. (1 oct. 2024)